Evidence map›Paper›PMID 39518106›Full record

ReviewCancers2024

Design Principles and Applications of Fluorescent Kinase Inhibitors for Simultaneous Cancer Bioimaging and Therapy.

Ab Majeed Ganai, Eirinaios I Vrettos, Stavroula G Kyrkou, Vasiliki Zoi, Tabasum Khan Pathan, Rajshekhar Karpoormath, Penelope Bouziotis, George A Alexiou, George A Kastis, Nicholas E Protonotarios and 1 more

Abstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ab Majeed GanaiDepartment of Chemistry, Section of Organic Chemistry and Biochemistry, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0002-2863-8837
Eirinaios I VrettosDepartment of Chemistry, Section of Organic Chemistry and Biochemistry, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0002-4801-1900
Stavroula G KyrkouDepartment of Chemistry, Section of Organic Chemistry and Biochemistry, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0003-4096-9046
Vasiliki ZoiNeurosurgical Institute, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0003-4655-9726
Tabasum Khan PathanDepartment of Chemistry, Section of Organic Chemistry and Biochemistry, University of Ioannina, 45110 Ioannina, Greece.
Rajshekhar KarpoormathDepartment of Pharmaceutical Chemistry, Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal (Westville), Durban 4000, South Africa.ORCID 0000-0002-1247-5754
Penelope BouziotisInstitute of Nuclear and Radiological Science and Technology, Energy and Safety (INRASTES), National Center for Scientific Research "Demokritos", 15310 Athens, Greece.ORCID 0000-0001-6778-2201
George A AlexiouNeurosurgical Institute, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0003-0257-4481
George A KastisInstitute of Nuclear and Radiological Science and Technology, Energy and Safety (INRASTES), National Center for Scientific Research "Demokritos", 15310 Athens, Greece.ORCID 0000-0002-1283-0883
Nicholas E ProtonotariosInstitute of Nuclear and Radiological Science and Technology, Energy and Safety (INRASTES), National Center for Scientific Research "Demokritos", 15310 Athens, Greece.ORCID 0000-0002-7701-5644
Andreas G TzakosDepartment of Chemistry, Section of Organic Chemistry and Biochemistry, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0001-6391-0288

Funding

European Regional Development Fund of the European Union and Greek national funds TAEDK-06189/ Τ2EDK-0326
6 · The paper itself

Abstract

Kinase inhibitors are potent therapeutic agents in cancer treatment, but their effectiveness is frequently restricted by the inability to image the tumor microenvironment. To address this constraint, kinase inhibitor-fluorophore conjugates have emerged as promising theranostic agents, allowing for simultaneous cancer diagnosis and treatment. These conjugates are gaining attention for their ability to visualize malignant tissues and concurrently enhance therapeutic interventions. This review explores the design principles governing the development of multimodal inhibitors, highlighting their potential as platforms for kinase tracking and inhibition via bioimaging. The structural aspects of constructing such theranostic agents are critically analyzed. This work could shed light on this intriguing field and provide adequate impetus for developing novel theranostic compounds based on small molecule inhibitors and fluorophores.

Indexed as

bioimagingconjugatesdesign principleskinase inhibitorstheranostic agents

Identifiers

PMID39518106
PMCPMC11545566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.